EORTC/SIOPE partnership to maximize quality of paediatric radiotherapy

The EORTC recently entered a partnership program with the European Society for Paediatric Oncology (SIOPe). The QUARTET project aims to establish a cross-European quality assurance platform for clinical trials using radiation therapy in the treatment of children and adolescents.

“Our goals are to increase cure rate in children and adolescents with cancer as well as the quality of life of childhood cancer survivors,” said Gilles Vassal, SIOPe President. “The partnership with EORTC will improve the quality of radiation therapy and contribute to these aims.”

“Quality assurance is essential in radiotherapy to ensure patients get the most benefit from their treatment with the minimum amount of risk,” said Samira Essiaf, Chief Executive Officer at SIOPe. “This project will help establish clear references for the reliable and efficient use of radiation therapy in paediatric oncology, and the EORTC’s rigorous quality control expertise in radiotherapy is key in our decision to enter in this partnership.”

“We are honored to be partnering with SIOPe to contribute to this important cross-European project,” said Yan Liu, clinical leader, medical department at EORTC. “Their dedication to improving quality of care and treatment for paediatric oncology patients is fundamentally aligned with the EORTC’s mission to improve treatment for all cancer patients.”

More information on the SIOPe website.

Back to news list

Related News

  • EORTC Quality of Life Group celebrating 40 years

  • Results of two EORTC studies have been published in NEJM and the Lancet Oncology

  • Interview with Winette van der Graaf: enhanced patient participation in trials may help make cancer research more heterogeneous

  • New results, updates, and forthcoming EORTC trials in melanoma, soft tissue sarcoma, head and neck, testicular and lung cancer presented at ESMO 2022

  • Important new data from EORTC trials to be presented at ESMO 2022

  • EORTC Item Library provides considerable coverage of CTCAE side effects, new study finds

  • EORTC Completes Patient Recruitment to Study of Treatment for unresectable or metastatic melanoma

  • In Memoriam: Dr Martin Charles Mihm

  • The 1500th patient has been enrolled in the E²-RADIatE cohort OLIGOCARE (RP-1822)

  • PRESS RELEASE: Better treatment for better health: lifting the veil on treatment optimisation